You probably know someone taking one of these shots. Ozempic, Wegovy, Mounjaro, and Zepbound have become part of ordinary life for weight loss and type 2 diabetes. Now the federal regulator wants the labels to say something new.
On November 9, 2026, the FDA told the makers of every GLP-1 drug to add a warning about a rare eye condition called NAION. The full name is non-arteritic anterior ischemic optic neuropathy.
NAION can cause sudden, painless vision loss in one eye. The damage is usually permanent.
It happens when blood flow to the front of the optic nerve drops. The optic nerve carries images from the eye to the brain. If part of it is starved of blood, that signal is cut.
Also read: Five breathing techniques that may calm anxiety in just a few minutes
Vision can blur, dim, or black out in one eye. Many patients first notice it when they wake up.
What the pooled trial data actually show
The agency based its decision on a pooled analysis of 126 randomized trials covering more than 134,000 patients. According to NBC News, users of GLP-1 drugs had about 6.4 cases of NAION per 100,000 person-years.
People on placebo or other glucose-lowering medications had about 3.8 cases per 100,000 person-years. In plain terms, the GLP-1 rate was almost double the comparison group.
That is still a small absolute risk. The FDA decided the signal was strong enough to flag, but the agency is not pulling any drug from the market.
Also read: How eating tomatoes every day may affect your heart and cancer risk
The warning will go into the Warnings and Precautions section of every GLP-1 drug in the class. That includes Novo Nordisk's Ozempic and Wegovy, both built on semaglutide, the active ingredient in the popular weekly shot.
It also covers Eli Lilly's Mounjaro and Zepbound, built on tirzepatide. Older diabetes drugs like Trulicity, Victoza, and Rybelsus are in the same class and get the same language.
Symptoms and what to do
Signs of NAION include sudden blurred or dim vision in one eye, a blind spot, or faded colors. Many patients notice the change on waking.
The FDA advises patients to call a health care provider right away if they see sudden vision loss in one eye, especially after sleep.
Also read: What your gums can reveal about your heart health and disease risk
The agency also tells doctors to consider stopping the GLP-1 drug in patients who develop NAION, unless the benefits of staying on treatment clearly outweigh the risk.
The warning builds on earlier research. A 2024 study in JAMA Ophthalmology led by researchers at Massachusetts Eye and Ear was the first to flag the possible link between semaglutide and NAION. Follow-up studies showed smaller but similar signals.
Novo Nordisk told NBC News that available research does not establish that its medicines cause NAION. The company said it will update the labels as the agency requires.
Patients already on a GLP-1 drug should not stop on their own. The FDA's guidance is to keep taking the medication and contact the prescribing doctor the moment any vision change appears.
Also read: Not all cannabis users face the same addiction risk, study finds
Also read: How eating processed meat every day may affect your cancer and heart risk
This article is made and published by Mie Hermansen, who may have used AI in the preparation.